UCB FY Consensus Earnings Estimates (Average) In € million 2025a 2026e 2027e 2028e 2029e 2030e 2031e Net Sales Number of Estimates 13 13 13 12 12 11 Highest 8,976 10,915 12,529 12,836 13,798 15,014 Consensus (Mean) 7,388 8,634 9,750 10,902 11,776 12,661 13,297 Lowest 8,159 9,061 10,110 10,815 11,483 12,017 Revenue Number of Estimates 15 15 15 14 14 12 Highest 9,593 11,278 12,913 14,146 15,455 15,486 Consensus (Mean) 7,741 9,076 10,107 11,222 12,250 13,156 13,619 Lowest 8,477 9,333 10,426 11,131 11,800 12,335 Research and Development expenses Number of Estimates 14 14 14 13 13 12 Highest 2,141 2,579 2,774 2,856 3,015 3,079 Consensus (Mean) 1,822 2,047 2,271 2,421 2,572 2,675 2,645 Lowest 1,846 2,030 2,195 2,230 2,210 1,200 Marketing & Selling expenses Number of Estimates 10 10 10 10 10 9 Highest 2,773 3,026 3,263 3,466 3,702 3,737 Consensus (Mean) 2,485 2,665 2,884 3,094 3,214 3,320 3,379 Lowest 2,574 2,730 2,849 2,934 3,010 2,859 General and administrative expenses Number of Estimates 10 10 10 10 10 9 Highest 364 380 417 459 482 497 Consensus (Mean) 264 290 309 328 343 356 369 Lowest 257 258 261 263 266 269 Other operating (income)/expenses Number of Estimates 14 14 14 14 14 12 Highest -613 -648 -672 -686 -696 -659 Consensus (Mean) -829 -823 -948 -1,037 -1,116 -1,196 -1,188 Lowest -983 -1,131 -1,263 -1,359 -1,621 -1,828 Adjusted EBIT Number of Estimates 15 15 15 14 14 12 Highest 3,209 3,723 4,487 5,422 6,345 6,955 Consensus (Mean) 2,009 2,768 3,192 3,781 4,403 4,989 5,433 Lowest 2,219 2,779 3,194 3,791 4,128 4,359 Adjusted EBITDA Number of Estimates 14 14 14 13 13 11 Highest 3,858 4,414 5,319 6,351 7,380 8,081 Consensus (Mean) 2,636 3,427 3,945 4,559 5,234 5,866 6,250 Lowest 2,896 3,470 3,844 4,441 5,006 5,292 Adj. EBITDA ratio Number of Estimates Highest Consensus (Mean) 34.05% 37.76% 39.04% 40.62% 42.73% 44.59% 45.89% Lowest Net Profit Number of Estimates 11 11 11 11 11 9 Highest 2,645 2,933 3,589 4,254 4,808 5,170 Consensus (Mean) 1,604 2,253 2,566 3,045 3,586 4,090 4,367 Lowest 1,747 2,134 2,605 3,095 3,379 3,626 Core EPS (€) Number of Estimates 12 12 12 12 12 10 Highest 14.93 17.54 21.99 26.79 31.68 35.28 Consensus (Mean) 9.78 13.46 15.37 18.04 20.85 23.68 26.07 Lowest 11.21 13.18 15.73 17.74 19.05 20.23 UCB FY Consensus Product Sales Estimates (Average) In € million 2025a 2026e 2027e 2028e 2029e 2030e 2031e Product Portfolio Cimzia Number of Estimates 13 13 13 12 12 11 Highest 2,105 2,101 1,934 1,815 1,722 1,642 Consensus (Mean) 1,954 1,958 1,869 1,691 1,478 1,329 1,206 Lowest 1,842 1,681 1,430 1,100 950 835 Bimzelx Number of Estimates 13 13 13 12 12 12 Highest 3,893 5,753 7,047 7,028 7,758 8,522 Consensus (Mean) 2,227 3,518 4,645 5,707 6,511 7,226 7,732 Lowest 3,180 4,088 5,040 5,702 6,130 6,439 Evenity* Number of Estimates 13 13 13 12 12 11 Highest 204 248 297 342 376 395 Consensus (Mean) 137 186 224 255 279 296 287 Lowest 167 201 228 240 252 208 Rystiggo Number of Estimates 13 13 13 12 12 11 Highest 450 583 720 885 1,038 1,172 Consensus (Mean) 332 429 536 633 706 767 816 Lowest 403 495 573 629 661 684 Zilbrysq Number of Estimates 13 13 13 12 12 11 Highest 435 588 698 797 926 1,044 Consensus (Mean) 217 323 424 515 598 652 705 Lowest 266 348 435 491 535 557 Vimpat Number of Estimates 13 13 13 12 12 11 Highest 251 219 195 195 195 195 Consensus (Mean) 303 210 182 160 144 131 120 Lowest 188 152 124 98 78 62 Keppra Number of Estimates 13 13 13 12 12 11 Highest 438 409 400 400 380 360 Consensus (Mean) 439 410 372 341 319 297 276 Lowest 363 309 262 224 186 159 Briviact Number of Estimates 13 13 13 12 12 11 Highest 563 448 430 447 459 469 Consensus (Mean) 758 498 287 235 215 197 187 Lowest 448 170 107 85 77 69 Fintepla Number of Estimates 13 13 13 12 12 11 Highest 557 687 807 934 1,078 1,079 Consensus (Mean) 427 517 626 708 763 801 795 Lowest 500 579 637 666 600 540 Nayzilam Number of Estimates 13 13 13 12 12 11 Highest 177 203 223 210 214 218 Consensus (Mean) 128 168 179 174 149 129 122 Lowest 143 150 143 103 50 50 Kygevvi Number of Estimates 1 9 10 10 10 10 9 Highest 0 47 95 142 190 237 291 Consensus (Mean) 0 23 45 71 99 130 144 Lowest 0 10 13 20 25 30 35 Potential New Products non-risk adjusted Dapirolizumab pegol Number of Estimates 1 2 2 5 7 8 8 Highest 0 0 0 290 522 783 1,018 Consensus (Mean) 0 0 0 78 176 283 429 Lowest 0 0 0 0 30 50 113 Staccato alprazolam Number of Estimates 2 3 5 7 7 7 6 Highest 0 0 81 146 211 276 222 Consensus (Mean) 0 0 33 58 102 143 151 Lowest 0 0 0 7 10 13 17 Rezanecel Number of Estimates 1 1 1 3 4 5 Highest 0 0 0 65 167 526 Consensus (Mean) 0 0 0 25 117 293 Lowest 0 0 0 0 0 70 Bepranemab Number of Estimates 1 2 2 4 4 5 5 Highest 0 0 0 165 413 600 873 Consensus (Mean) 0 0 0 55 156 217 363 Lowest 0 0 0 0 9 30 180 Galvokimig (UCB9741) Number of Estimates 1 2 2 3 5 6 7 Highest 0 0 0 0 300 650 800 Consensus (Mean) 0 0 0 0 90 341 451 Lowest 0 0 0 0 0 171 103 Cizutamig Number of Estimates 1 1 1 1 2 3 Highest 0 0 0 0 10 210 Consensus (Mean) 0 0 0 0 5 103 Lowest 0 0 0 0 0 0 *European sales, ex-EU sales booked by Amgen/Astellas